Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06911632 · ClinicalTrials.gov registry record · NA

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

A NA study of Pulmonary Hypertension and Interstitial Lung Disease (ILD), sponsored by Tempus AI.

Active
Registry status
NA
Development phase
1,000
Enrollment target
20
Study locations

NCT06911632: Active NA study of Pulmonary Hypertension and Interstitial Lung Disease (ILD), sponsored by Tempus AI.

NCT06911632 is a NA study of Pulmonary Hypertension and Interstitial Lung Disease (ILD) that is active but no longer recruiting, run by Tempus AI. The registered enrollment target is 1,000 participants, above the 600-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (67% higher). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06911632, a NA study of Pulmonary Hypertension and Interstitial Lung Disease (ILD), is active but no longer recruiting, sponsored by Tempus AI.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
1,000 participants
Enrollment target
20
Study locations

Study Summary

MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.

Primary Outcome

Mean pulmonary artery pressure (mPAP) \> 20 mm Hg and pulmonary vascular resistance (PVR) \> 2 Wood units

Interventions

  • DEVICE ECG-based AI Device - Results Returned to Investigator
  • PROCEDURE Echocardiogram and Right Heart Catheterization
  • DEVICE ECG-based AI Device - Results Not Returned to Investigator

Study Locations (20)

Arizona

  • Banner University Medical Center - Phoenix
  • Dignity Health - St. Joseph's Hospital and Medical Center-Norton Thoracic Institute - Phoenix

Illinois

  • Northwestern University - Chicago
  • University of Illinois Health - Chicago

Indiana

  • Indiana University Health Methodist Hospital - Indianapolis
  • Community Health Network - Indianapolis

Alabama

  • University of Alabama at Birmingham - Birmingham

Colorado

  • National Jewish Health - Denver

Florida

  • AdventHealth Orlando - Orlando

Kentucky

  • University of Kentucky - Lexington

Louisiana

  • Louisiana State University Health Shreveport - Shreveport

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2025-07-23
Est. Completion 2028-07
Phase NA
Tempus AI

13 total trials

What the registry record for NCT06911632 still lists

NCT06911632 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 600-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (67% higher).

The record links to 2 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 3 interventions - of which ECG-based AI Device - Results Returned to Investigator is the first listed.

NCT06911632 names 20 study sites across 17 states, led by Arizona, Illinois, Indiana.

Frequently Asked Questions

What is clinical trial NCT06911632 about?

NCT06911632 is a clinical study titled "Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension". MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.

What is the current status of trial NCT06911632?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2025-07-23. Estimated completion is 2028-07.

What conditions does trial NCT06911632 study?

This clinical trial studies the following conditions: Pulmonary Hypertension, Interstitial Lung Disease (ILD).

What interventions are being tested in trial NCT06911632?

The interventions under investigation include: ECG-based AI Device - Results Returned to Investigator (DEVICE), Echocardiogram and Right Heart Catheterization (PROCEDURE), ECG-based AI Device - Results Not Returned to Investigator (DEVICE).

Who is sponsoring clinical trial NCT06911632?

This trial is sponsored by Tempus AI, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06911632 being conducted?

This trial has 20 study locations across Alabama, Arizona, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pulmonary Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06911632's enrollment target sits among peer trials

1,000 8th of 72 higher than 63 of 72 other Pulmonary Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pulmonary Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00018044 · 1,000 participants

    Study of Mycobacterial Infections

  • NCT01036581 · 1,000 participants · NA

    Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

  • NCT01192048 · 1,000 participants

    Genetics of Congenital Heart Disease

  • NCT01553214 · 1,000 participants · Phase 4

    Improving White Blood Cell Collection From Healthy Donors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06911632, the US trial registry maintained by the National Library of Medicine. NCT06911632 (large enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.